Sunday 8 November 2026 Export GILD’s income statement to Excel — free account

Gilead Sciences, Inc.

GILD

Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024.

Revenue: +6.83%
EPS: −20.5%
Free cash flow: +21.1%
Total debt: +5.17%

Quarter to September 2026, against a year earlier

166.89 0.68 −0.41%

Follow GILD

Alert me

Market cap: $207.8B
P/E: n/m
Fwd P/E: n/m
Dividend yield: 1.95%
F-score: 8/9
ROIC: −4.51%
Net debt / EBITDA: 1.4×
Dividend safety: 77/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Gilead Sciences, Inc. (GILD) P/B ratio

Alert me on P/B ratio

As of 6 November 2026, Gilead Sciences, Inc. (GILD) trades at a P/B ratio of 16.0×. Over the past ten years it has ranged from 3.4× (December 2018) to 16.7× (November 2026); the current reading is higher than 100% of that period. That is above the Drug Manufacturers General industry median of 5.3× and above the Healthcare sector median of 2.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/GILD/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Gilead Sciences, Inc. P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/GILD/metrics/pb-ratio">Gilead Sciences, Inc. (GILD) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	6.8×	12.80%
FY2024	6.0×	31.06%
FY2023	4.6×	(9.62%)
FY2022	5.1×	16.70%
FY2021	4.3×	7.73%
FY2020	4.0×	10.31%
FY2019	3.6×	(3.36%)
FY2018	3.8×	(20.19%)
FY2017	4.7×	(7.88%)
FY2016	5.1×	(33.84%)

Period	P/B ratio	Change
Sep 2026	14.3×	6.87%
Jun 2026	13.4×	81.01%
Mar 2026	7.4×	9.43%
Dec 2025	6.8×	4.98%
43 more quarters	Free account

Against its own ten years

Low 3.4× High 16.7×

Ten-year median 4.7×

Current reading's percentile 100

Company	P/B ratio
SNY Sanofi compare	1.4×
PFE Pfizer Inc. compare	1.9×
NVO Novo Nordisk A/S compare	5.3×
BMY Bristol Myers Squibb Company compare	5.4×
AZN AstraZeneca PLC compare	5.6×
MRK Merck & Co., Inc. compare	8.1×
NVS Novartis AG compare	8.2×
GILD Gilead Sciences, Inc.	16.0×
AMGN Amgen Inc. compare	17.4×
Drug Manufacturers General industry median	5.3×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

Gilead Sciences, Inc. (GILD) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on GILD

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on GILD

Stockrow Weekly